Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.41 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.41 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 2/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27375976 | 1.00 | CHRM5 (0.52) | CHRM5ADRA2CSLC6A1GABRA5GABRB2 | |
| SCHEMBL14505993 | 1.00 | CHRM5 (0.52) | CHRM5ADRA2CSLC6A1GABRA5GABRB2 | |
| SCHEMBL29862023 | 0.98 | CHRM5 (0.56) | CHRM5ADRA2CSLC6A1GABRA5GABRB2 | |
| Hydrochloric Acid SCHEMBL20520976 | 0.98 | CHRM5 (0.50) | CHRM5ADRA2CSLC6A1GABRA5GABRB2 | |
| Hydrochloric Acid SCHEMBL8449332 | 0.98 | CHRM5 (0.50) | CHRM5ADRA2CSLC6A1GABRA5GABRB2 | |
| SCHEMBL2462435 | 0.98 | CHRM5 (0.56) | CHRM5ADRA2CSLC6A1GABRA5GABRB2 | |
| SCHEMBL13950187 | 0.98 | CHRM5 (0.56) | CHRM5ADRA2CSLC6A1GABRA5GABRB2 | |
| Hydrochloric Acid SCHEMBL20520975 | 0.98 | CHRM5 (0.50) | CHRM5ADRA2CSLC6A1GABRA5GABRB2 | |
| Hydrochloric Acid SCHEMBL29134438 | 0.98 | CHRM5 (0.50) | CHRM5ADRA2CSLC6A1GABRA5GABRB2 | |
| SCHEMBL28249891 | 0.98 | CHRM5 (0.56) | CHRM5ADRA2CSLC6A1GABRA5GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HUFF SARAH ELIZABETH (US) | 2025-11-20 | — | — | US | disclosed |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20220409615-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. | 2022-12-29 | — | — | US | disclosed |
| EP-3601282-B1 | NOVEL PYRIDO[2,3-B]INDOLE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN LA ROCHE (CH) | 2021-07-21 | — | — | EP | disclosed |
| EP-3135672-A1 | COMPOSITIONS AND METHODS FOR TREATING ALCOHOL USE DISORDERS, PAIN AND OTHER DISEASES | VM Discovery, Inc. (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2118110-B1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-2205558-A1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF AS HISTAMINE H3 RECEPTOR MODULATORS | Sanofi-Aventis (FR) | 2010-07-14 | — | — | EP | disclosed |
| EP-2118110-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV INHIBITORS | Bristol-Myers Squibb Company (US) | 2009-11-18 | — | — | EP | disclosed |
| US-7538102-B2 | Compounds for the treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-26 | — | — | US | disclosed |
| WO-2009052063-A1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF AS HISTAMINE H3 RECEPTOR MODULATORS | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | disclosed |
| US-20080226592-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| WO-2008112851-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-18 | — | — | WO | disclosed |
| CN-1213026-C | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds | GPINIL HOLDINGS INC (US) | 2005-08-03 | — | — | CN | disclosed |
| CN-1041087-C | Arylacetamides | MERCK PATENT AG (DE) | 1998-12-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409615-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | CHRM5 4281/4885ADRA2C 3493/4885SLC6A1 382/4885 |
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | CHRM5 4638/4885ADRA2C 3695/4885SLC6A1 440/4885 |
| US-20080226592-A1 | Compounds for the Treatment of Hepatitis C | SLC10A1, HAVCR2, OAT | CHRM5 4544/4885ADRA2C 898/4885SLC6A1 1485/4885 |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | HTT, HYPK, ATXN2 | CHRM5 4281/4885ADRA2C 3493/4885SLC6A1 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.